»News »Sales license for enzyme tissue transglutaminase
Sales license for enzyme tissue transglutaminase
Celiac disease is a chronic inflammatory bowel disease caused by an incompatibility with gliadin. The disesase affects genetically predisposed individuals (HLA-DQ2, HLA-DQ8). During exposure to gliadin the enzyme tissue transglutaminase (tTG) is activated in the small intestine, leading to deamination of gliadin followed by its complexation on the extracellular matrix of mucosal cells. The resulting inflammatory reaction leads to large lesions of the mucosa and finally to a so-called “flat” mucosa, with malabsorption associated with nutrient deficiency as clinical symptoms.
In the course of the inflammatory reaction antibodies against gliadin and also against tissue transglutaminase can be found in the serum of patients. IgA antibodies against tTG show the best correlation to the severity of the inflammation and have therefore reached the highest diagnostic relevance. Celiac disease is often accompanied by an IgA deficiency. In these patients IgG antibodies against tTG provide the serological basis of diagnostics (REF 4044).
After a long term of proceedings, Generic Assays gained as one of only a few companies the selling-license for the antigene of enzyme tissue transglutaminase .
Our products according to this theme:
- 4033 Anti-hu TransG ELISA (anti-tTG IgG)
- 4044 Anti-hu tTG IgG ELISA (anti-tTG IgA)
- 4002 CeliAK IgG Dot (anti-Gliadin IgG, anti-tTG IgG)
- 4008 CeliAK Dot (anti-Gliadin IgA, anti-tTG IgA)
- 4086 GastrAK IgA Dot (anti-Gliadin, ASCA, anti-tTG IgA)4087 GastrAK IgG Dot (anti-Gliadin, ASCA, anti-tTG IgG)
Publications:
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997, 3, 797-801
Schuppan D, Hahn EG: IgA anti-tissue transglutaminase: setting the stage for celiac disease screening. Eur J Gastroenterol Hepatol. 2001, 13, 635-7.
